Search

Your search keyword '"Stockerl-Goldstein, Keith E."' showing total 432 results
Start Over Author "Stockerl-Goldstein, Keith E."
432 results on '"Stockerl-Goldstein, Keith E."'

1. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

Author

Rubinstein, Samuel M, Bhutani, Divaya, Lynch, Ryan C, Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A, Mishra, Sanjay, Mundt, Daniel P, Shah, Dimpy P, Sica, R Alejandro, Stockerl-Goldstein, Keith E, Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A, Cogan, Jacob C, Kc, Devendra, Friese, Christopher R, Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A, Joshi, Monika, Kasi, Anup, Klein, Elizabeth J, Koshkin, Vadim S, Kuderer, Nicole M, Kwon, Daniel H, Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H, McKay, Rana R, Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K, Olszewski, Adam J, Polimera, Hyma V, Portuguese, Andrew J, Puc, Matthew M, Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A, Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M, Zubiri, Leyre, Warner, Jeremy L, and Thompson, Michael A

Subjects
Rare Diseases, Clinical Research, Prevention, Cancer, Aetiology, 2.1 Biological and endogenous factors, COVID-19, COVID-19 Testing, Humans, Lymphatic Diseases, Neoplasms, Risk Factors, SARS-CoV-2, COVID-19 and Cancer Consortium
Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Published
2022

3. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, Warner, Jeremy L, Consortium, COVID-19 and Cancer, Abidi, Maheen, Acoba, Jared D, Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H, Azad, Nilo, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H, Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W, Busser, Fiona, Cabal, Angelo, Caimi, Paolo, and Carducci, Theresa

Subjects
Biomedical and Clinical Sciences, Health Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Aging, Prevention, Cancer, Lung, Good Health and Well Being, Aged, Antiviral Agents, Azithromycin, Betacoronavirus, COVID-19, Cause of Death, Comorbidity, Coronavirus Infections, Databases, Factual, Female, Humans, Hydroxychloroquine, Male, Middle Aged, Neoplasms, Pandemics, Pneumonia, Viral, Prognosis, Risk Factors, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19 and Cancer Consortium, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundData on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.MethodsIn this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.FindingsOf 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53-2·21), male sex (1·63, 1·07-2·48), smoking status (former smoker vs never smoked: 1·60, 1·03-2·47), number of comorbidities (two vs none: 4·50, 1·33-15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11-7·18), active cancer (progressing vs remission: 5·20, 2·77-9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79-4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07-0·84) or the US-Midwest (0·50, 0·28-0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.InterpretationAmong patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.FundingAmerican Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

Published
2020

9. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

Author

Barnell, Erica K., Newcomer, Kenneth F., Skidmore, Zachary L., Krysiak, Kilannin, Anderson, Sydney R., Wartman, Lukas D., Oh, Stephen T., Welch, John S., Stockerl-Goldstein, Keith E., Vij, Ravi, Cashen, Amanda F., Pusic, Iskra, Westervelt, Peter, Abboud, Camille N., Ghobadi, Armin, Uy, Geoffrey L., Schroeder, Mark A., Dipersio, John F., Politi, Mary C., Spencer, David H., Duncavage, Eric J., Ley, Timothy J., Griffith, Malachi, Jacoby, Meagan A., and Griffith, Obi L.

Published
2021
Full Text
View/download PDF

10. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

11. Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes

Author

Jacoby, Meagan A., primary, Welch, John S., additional, Westervelt, Peter, additional, Christopher, Matthew, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Stockerl-Goldstein, Keith E., additional, Kahl, Brad S., additional, Pusic, Iskra, additional, DiPersio, John F., additional, Schroeder, Mark A., additional, Kim, Miriam Y., additional, Fehniger, Todd A., additional, Ghobadi, Armin, additional, Gu, Christine J., additional, Anderson, Wade, additional, Vanderlaag, Kathryn, additional, Ali, Kamran, additional, Pataki, Camille, additional, and Lacher, Markus D., additional

Published
2023
Full Text
View/download PDF

12. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

13. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Tables from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figures from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

20. Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Author

Loncharich, Alexa J, primary, Fiala, Mark A, additional, Slade, Michael J, additional, Vickroy, Angela, additional, Kavanaugh, Margaret, additional, Wilson, Kari, additional, Schroeder, Mark A., additional, Stockerl-Goldstein, Keith E, additional, Vij, Ravi, additional, and Sanfilippo, Kristen M., additional

Published
2022
Full Text
View/download PDF

21. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Author

Schroeder, Mark A., primary, Choi, Jaebok, additional, Atluri, Himachandana, additional, Atkins, Jordan, additional, Harding, Melinda, additional, Eisele, Jeremy, additional, Gao, Feng, additional, Abboud, Ramzi, additional, Abboud, Camille, additional, Cashen, Amanda F., additional, Christopher, Matthew, additional, Fehniger, Todd A., additional, Ferraro, Francesca, additional, Ghobadi, Armin, additional, Jacoby, Meagan A., additional, Pusic, Iskra, additional, Stockerl-Goldstein, Keith E, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Walter, Matthew J, additional, Westervelt, Peter, additional, and DiPersio, John F., additional

Published
2022
Full Text
View/download PDF

22. Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Author

Edmisson, Jacob, primary, Fiala, Mark A, additional, Slade, Michael J, additional, Vickroy, Angela, additional, Kavanaugh, Margaret, additional, Wilson, Carmen, additional, Xiang, Jingyu, additional, Crees, Zachary D., additional, Schroeder, Mark A., additional, Stockerl-Goldstein, Keith E, additional, DiPersio, John F., additional, and Vij, Ravi, additional

Published
2022
Full Text
View/download PDF

23. Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Author

Slade, Michael J, primary, Khalid, Abir, additional, Fiala, Mark A, additional, Liyasova, Mariya, additional, Zaydman, Mark A, additional, McDonald, Zac, additional, Fortier, Julie M, additional, Kelley, Sarah, additional, Crees, Zachary D., additional, Schroeder, Mark A., additional, Stockerl-Goldstein, Keith E, additional, Yang, Liqiang, additional, and Vij, Ravi, additional

Published
2022
Full Text
View/download PDF

24. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Author

Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Jr., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, and Vij, Ravi

Published
2018
Full Text
View/download PDF

26. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M, Bhutani, Divaya, Lynch, Ryan C, Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A, Mishra, Sanjay, Mundt, Daniel P, Shah, Dimpy P, Sica, R Alejandro, Stockerl-Goldstein, Keith E, Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A, Cogan, Jacob C, Kc, Devendra, Friese, Christopher R, Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A, Joshi, Monika, Kasi, Anup, Klein, Elizabeth J, Koshkin, Vadim S, Kuderer, Nicole M, Kwon, Daniel H, Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H, McKay, Rana R, Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K, Olszewski, Adam J, Polimera, Hyma V, Portuguese, Andrew J, Puc, Matthew M, Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A, Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M, Zubiri, Leyre, Warner, Jeremy L, Thompson, Michael A, and COVID-19 and Cancer Consortium

Subjects
SARS-CoV-2, Prevention, COVID-19, COVID-19 Testing, Rare Diseases, COVID-19 and Cancer Consortium, Risk Factors, Clinical Research, Neoplasms, Humans, 2.1 Biological and endogenous factors, Aetiology, Lymphatic Diseases, Cancer
Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Published
2022

29. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Author

Berrien-Elliott, Melissa M., Becker-Hapak, Michelle, Cashen, Amanda F., Jacobs, Miriam, Wong, Pamela, Foster, Mark, McClain, Ethan, Desai, Sweta, Pence, Patrick, Cooley, Sarah, Brunstein, Claudio, Gao, Feng, Abboud, Camille N., Uy, Geoffrey L., Westervelt, Peter, Jacoby, Meagan A., Pusic, Iskra, Stockerl-Goldstein, Keith E., Schroeder, Mark A., DiPersio, John F., Soon-Shiong, Patrick, Miller, Jeffrey S., and Fehniger, Todd A.

Published
2022
Full Text
View/download PDF

32. Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Author

Crees, Zachary D., primary, Retting, Michael, additional, Jayasinghe, Reyka G, additional, Stockerl-Goldstein, Keith E., additional, Vainstein, Abi, additional, Sorani, Ella, additional, Ickowicz, Debby, additional, Shemesh-Darvish, Liron, additional, Kadosh, Shaul, additional, and DiPersio, John F., additional

Published
2021
Full Text
View/download PDF

33. Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Author

Crees, Zachary D., primary, Stockerl-Goldstein, Keith E., additional, Retting, Michael, additional, Larson, Sarah M, additional, Illes, Arpad, additional, Milone, Giuseppe, additional, Martino, Massimo, additional, Stiff, Patrick, additional, Sborov, Douglas W., additional, Pereira, Denise L., additional, Micallef, Ivana N., additional, Moreno Jiménez, Gemma, additional, Mikala, Gábor, additional, Paciello Coronel, Maria Liz, additional, Holtick, Udo, additional, Hiemenz, John W., additional, Qazilbash, Muzaffar H., additional, Hardy, Nancy M., additional, Latif, Tahir, additional, García-Cadenas, Irene, additional, Sorani, Ella, additional, Shemesh-Darvish, Liron, additional, Vainstein, Abi, additional, Kadosh, Shaul, additional, and DiPersio, John F., additional

Published
2021
Full Text
View/download PDF

34. Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Author

Crees, Zachary D., primary, Stockerl-Goldstein, Keith E., additional, Larson, Sarah, additional, Illés, Árpád, additional, Milone, Giuseppe, additional, Martino, Massimo, additional, Stiff, Patrick, additional, Sborov, Douglas W., additional, Pereira, Denise L., additional, Micallef, Ivana N., additional, Moreno Jiménez, Gemma, additional, Mikala, Gábor, additional, paciello Coronel, Maria liz, additional, Holtick, Udo, additional, Hiemenz, John W., additional, Qazilbash, Muzaffar H., additional, Hardy, Nancy M., additional, Latif, Tahir, additional, García-Cadenas, Irene, additional, Vainstein, Abi, additional, Sorani, Ella, additional, Gliko-Kabir, Irit, additional, Goldstein, Inbal, additional, Kadosh, Shaul, additional, and DiPersio, John F., additional

Published
2021
Full Text
View/download PDF

35. A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

Author

Jacoby, Meagan A., primary, Sallman, David A., additional, Scott, Bart L., additional, Haney, Megan, additional, Wan, Fei, additional, DiPersio, John F., additional, Abboud, Ramzi, additional, Stockerl-Goldstein, Keith E., additional, Komrokji, Rami S., additional, Schroeder, Mark A., additional, Walter, Matthew J., additional, Westervelt, Peter, additional, and Uy, Geoffrey L., additional

Published
2021
Full Text
View/download PDF

37. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Author

Abboud, Ramzi, primary, Gao, Feng, additional, Rettig, Michael P., additional, Eisele, Jeremy, additional, Gehrs, Leah, additional, Wallace, Nichols, additional, Abboud, Camille, additional, Westervelt, Peter, additional, Uy, Geoffrey L., additional, Cashen, Amanda F., additional, Christopher, Matt, additional, Ghobadi, Armin, additional, Jacoby, Meagan A., additional, Pusic, Iskra, additional, Stockerl-Goldstein, Keith E., additional, DiPersio, John F., additional, and Schroeder, Mark A., additional

Published
2021
Full Text
View/download PDF

40. Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Author

Rubinstein, Samuel, Lynch, Ryan C., Desai, Aakash, Stratton, Catherine, Jha, Alokkumar, Bakouny, Ziad, Schmidt, Andrew, Sica, R. Alejandro, Bhutani, Divaya, Shah, Dimpy P., Wall, Sarah A, Lyman, Gary H., Kuderer, Nicole M., Weiss, Matthias, Warner, Jeremy L., Stockerl-Goldstein, Keith E., Mesa, Ruben, and Thompson, Michael A.

Published
2020
Full Text
View/download PDF

42. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

Author

Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, and Nooka, Ajay K.

Subjects
Adult, Cyclopropanes, Male, Acetates, Sulfides, Drug Administration Schedule, Discipline, Antineoplastic Agents, Immunological, Humans, Clinical Trials, Infusions, Intravenous, Drug Approval, Aged, Aged, 80 and over, Antibodies, Monoclonal, Original Articles, Middle Aged, daratumumab, Survival Analysis, United States, Injection Site Reaction, multiple myeloma, Treatment Outcome, montelukast, Quinolines, Original Article, Female, monoclonal antibodies, Neoplasm Recurrence, Local, CD38
Abstract

Background Daratumumab is a human CD38‐directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). Methods A multicenter, open‐label treatment protocol provided early access to daratumumab for patients who had progressive MM after they received ≥3 prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent or if they were refractory to both a proteasome inhibitor and an immunomodulatory agent. Patients received daratumumab 16 mg/kg weekly for 8 weeks, every other week for 16 weeks, and monthly until they developed disease progression, unacceptable toxicity, or 60 days after the drug gained US approval. Treatment‐emergent grade ≥3 adverse events (AEs), serious AEs, and AEs of special interest were collected. Results Three hundred forty‐eight patients were enrolled at 39 US sites between June and December 2015. Patients received study therapy for a median of 1.9 months (range, 0.03‐6.0 months). Fifty‐two percent of patients transitioned to commercially‐available daratumumab and 37% discontinued because of progressive disease. Grade ≥3 AEs occurred in 50% of patients, including thrombocytopenia (15%) and anemia (14%). Serious AEs occurred in 35% of patients (12% were drug‐related), including infections (11%). Infusion reactions occurred in 56%, 2%, and 2% of patients during the first, second, and all subsequent infusions, respectively; respiratory symptoms (cough, dyspnea, throat irritation, nasal congestion) were common. The infusion reaction rate for the first infusion was 38% in 50 patients at 2 sites who received montelukast as premedication for their first infusion and 59% in patients who did not receive montelukast. Conclusions The current findings are consistent with previously reported trials and confirm the safety profile of daratumumab in heavily pretreated US patients who have relapsed or refractory MM. Cancer 2018;124:000‐000., An early access treatment protocol confirms the safety profile of daratumumab in patients with relapsed or refractory myeloma. Findings from 2 study sites (60 patients) that used montelukast premedication indicate reduced infusion reactions and infusion time associated with the first dose of daratumumab.

Published
2018

44. Protective conditioning for acute graft-versus-host disease

Author

Lowsky, Robert, Takahashi, Tsuyoshi, Yin Ping Liu, Dejbakhsh-Jones, Sussan, Grumet, F. Carl, Shizuru, Judith A., Laport, Ginna G., Stockerl-Goldstein, Keith E., Johnston, Laura J., Hoppe, Richard T., Bloch, Daniel A., Blume, Karl G., Negrin, Robert S., and Strober, Samuel

Subjects
Graft versus host reaction -- Risk factors, Graft versus host reaction -- Care and treatment, Globulin -- Research, Hematopoietic growth factors -- Research
Abstract

Several patients suffering from lymphoid malignant diseases are conditioned with total lymphoid irradiation plus antithymocyte globulin followed by hematopoietic-cell transplantation. Observations reveal that the occurrence of severe graft-versus-host disease (GVHD) in humans as with mice is reduced with such a treatment.

Published
2005

45. Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., additional, Cubitt, Celia C., additional, Neal, Carly C., additional, Wong, Pamela, additional, Wagner, Julia A., additional, Foster, Mark, additional, Schappe, Timothy, additional, Desai, Sweta, additional, McClain, Ethan, additional, Becker-Hapak, Michelle, additional, Foltz, Jennifer A., additional, Cooper, Matthew L., additional, Jaeger, Natalia, additional, Srivatsan, Sridhar Nonavinkere, additional, Gao, Feng, additional, Romee, Rizwan, additional, Abboud, Camille N., additional, Uy, Geoffrey L., additional, Westervelt, Peter, additional, Jacoby, Meagan A., additional, Pusic, Iskra, additional, Stockerl-Goldstein, Keith E., additional, Schroeder, Mark A., additional, DiPersio, John, additional, and Fehniger, Todd A., additional

Published
2020
Full Text
View/download PDF

46. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, primary, Aboulafia, David M., additional, Accordino, Melissa K., additional, Acoba, Jared D., additional, Ahluwalia, Manmeet S., additional, Ahmad, Syed A., additional, Ajmera, Archana, additional, Alimohamed, Saif I., additional, Altman, Jessica, additional, Angevine, Anne H., additional, Bakouny, Ziad, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill S., additional, Barrow McCollough, Briana, additional, Bashir, Babar, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios S., additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bhutani, Divaya, additional, Bilen, Mehmet A., additional, Bindal, Poorva, additional, Bishnoi, Rohit, additional, Blau, Sibel, additional, Bohachek, Pamela, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bouganim, Nathaniel, additional, Bowles, Daniel W., additional, Busser, Fiona J., additional, Butt, Omar, additional, Cabal, Angelo, additional, Cabalona, Wilhelmina D., additional, Cabebe, Elwyn C., additional, Caimi, Paolo, additional, Campian, Jian L., additional, Carducci, Theresa M., additional, Chen, James L., additional, Cheng, Alex, additional, Chism, David D., additional, Choueiri, Toni K., additional, Clark, Melanie J., additional, Clement, Jessica M., additional, Connors, Jean M., additional, Cook, Erin, additional, Curran, Catherine R., additional, Daher, Ahmad, additional, Dailey, Mark E., additional, Davis, Elizabeth J., additional, Dawsey, Scott J., additional, Deeken, John F., additional, Del Prete, Salvatore A., additional, Demetri, George D., additional, Desai, Aakash, additional, Doroshow, Deborah B., additional, Durbin, Eric B., additional, Egan, Pamela C., additional, Elias, Rawad, additional, Elkrief, Arielle, additional, Elms, Destry J., additional, Elshoury, Amro, additional, Faller, Bryan, additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Ferrario, Cristiano, additional, Fiala, Mark A., additional, Flora, Daniel B., additional, French, Benjamin, additional, Friese, Christopher R., additional, Fu, Julie C., additional, Gadgeel, Shirish M., additional, Gainor, Justin, additional, Galsky, Matthew D., additional, Gantt, Gerald, additional, Garcia, Jorge A., additional, Gartrell, Benjamin A., additional, Gatti-Mays, Margaret E., additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Glover, Michael J., additional, Goel, Sanjay, additional, Graber, Jerome J., additional, Griffiths, Elizabeth A., additional, Grivas, Petros, additional, Grover, Punita, additional, Gulati, Anthony P., additional, Gulati, Shuchi, additional, Gupta, Shilpa, additional, Gurley, Michael, additional, Hafez, Navid, additional, Halabi, Susan, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hausrath, Daniel J., additional, Hawley, Jessica E., additional, Hennessy, Cassandra, additional, Herbst, Roy S., additional, Hershman, Dawn L., additional, Hoppenot, Claire, additional, Hoskins, Kent F., additional, Hoyo-Ulloa, Irma, additional, Hsu, Emily, additional, Hsu, Chih-Yuan, additional, Hwang, Clara, additional, Islam, Jessica Yasmine, additional, Jabbour, Salma K., additional, Jani, Chinmay, additional, Jha, Alokkumar, additional, Jhawar, Sachin R., additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kasi, Anup, additional, Kelleher, Kaitlin, additional, Kennecke, Hagen F., additional, Khaki, Ali Raza, additional, Khan, Hina, additional, Khan, Mahir, additional, Kharofa, Jordan, additional, Kloecker, Goetz, additional, Knoble, Jeanna L., additional, Kulkarni, Amit A., additional, Kumar, Vaibhav, additional, Lammers, Philip E., additional, Leighton, John C., additional, Lemmon, Christopher A., additional, Lewis, Mark A., additional, Li, Ang, additional, Li, Xuanyi, additional, Liu, Stephen V., additional, Lo, K.M., additional, Loaiza-Bonilla, Arturo, additional, Logan, Barbara B., additional, Loggers, Elizabeth T., additional, de Lima Lopes, Gilberto, additional, Loree, Jonathan M., additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Lyman, Gary H., additional, Lynch, Ryan C., additional, Madhavan, Subha, additional, Mahadevan, Daruka, additional, Mahmood, Sana Z., additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H., additional, Masters, Tyler, additional, Mavromatis, Blanche H., additional, McKay, Rana R., additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Menendez, Alvaro G., additional, Menon, Harry, additional, Mesa, Ruben A., additional, Mico, Vasil, additional, Miller, Chaim, additional, Mishra, Sanjay, additional, Monahan, Ryan S., additional, Morgans, Alicia K., additional, Mulcahy, Mary F., additional, Mundt, Daniel, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Nakasone, Elizabeth S., additional, Nakayama, John M., additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan H., additional, Nizam, Amanda, additional, Nohria, Anju, additional, Nuzzo, Pier Vitale, additional, Ohri, Nitin, additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Painter, Corrie A., additional, Palmer, Joshua D., additional, Panagiotou, Orestis A., additional, Park, Cathleen, additional, Pasquinelli, Mary M., additional, Patel, Jaymin M., additional, Patel, Kanishka G., additional, Peddi, Prakash, additional, Pennell, Nathan A., additional, Peters, Solange, additional, Pilar, Christine, additional, Pillainayagam, Clement, additional, Puc, Matthew, additional, Ramirez, Amelie G., additional, Rathmann, Joerg, additional, Ravindranathan, Deepak, additional, Reid, Sonya A., additional, Reuben, Daniel Y., additional, Revankar, Sanjay G., additional, Reynolds, Kerry L., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riess, Jonathan, additional, Rini, Brian I., additional, Rink, Cameron, additional, Rosen, Lane R., additional, Rosenstein, Lori J., additional, Rosovsky, Rachel P., additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Rubinstein, Samuel M., additional, Saif, M. Wasif, additional, Salazar, Mary, additional, Santos Dutra, Miriam, additional, Schapira, Lidia, additional, Schmidt, Andrew L., additional, Schroeder, Brett A., additional, Schwartz, Gary K., additional, Schwartz, Candice, additional, Schweizer, Michael T., additional, Serrano, Oscar K., additional, Shafer, Danielle A., additional, Shah, Pankil K., additional, Shah, Dimpy, additional, Shah, Mansi R., additional, Shah, Sumit A., additional, Shah, Chintan, additional, Shaw, Grace, additional, Shaya, Justin A., additional, Shyr, Yu, additional, Slosky, David A., additional, Smits, Melissa, additional, Solorzano, Carmen C., additional, Stauffer, Karen, additional, Stockerl-Goldstein, Keith E., additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Streckfuss, Mitrianna, additional, Subbiah, Suki, additional, Tachiki, Lisa, additional, Tadesse, Eyob, additional, Thompson, Michael A., additional, Topaloglu, Umit, additional, Tucker, Matthew D., additional, Van Allen, Eliezer M., additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta K., additional, Verma, Amit, additional, Vikas, Praveen, additional, Vinayak, Shaveta, additional, Vinh, Donald C., additional, Wagner, Michael J., additional, Wall, Sarah, additional, Wang, Lucy L., additional, Warner, Jeremy L., additional, Wehbe, Firas H., additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Weissmann, Lisa B., additional, Wildes, Tanya M., additional, Williams, Nicole, additional, Wise-Draper, Trisha M., additional, Wood, William A., additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Xu, Wenxin, additional, Yeh, Albert C., additional, Yu, Irene S., additional, Yu, Peter Paul, additional, Zacks, Rosemary, additional, Zaman, Qamar Ul, additional, Zaren, Howard, additional, Zhang, Tian, additional, Zhou, Alice Y., additional, Zhu, Huili, additional, Zon, Rebecca L., additional, and Zubiri, Leyre, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results